Cryoballoon pulmonary vein isolation: Double stack vs standard ablation
Heart Rhythm · 2025
DOI: 10.1016/j.hrthm.2025.01.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Heart Rhythm, 2025. Verfasst von Seth Kibel und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Pulmonary Veins, Cryosurgery, Atrial Fibrillation, Catheter Ablation. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The results of pulmonary vein isolation (PVI) are limited by arrhythmia recurrence, which is most often due to failure to effectuate a durable contiguous circumferential transmural lesion around the pulmonary vein ostia. OBJECTIVE: We sought to determine if enhancing the index ablation line through the use of multiple cryoballoon diameters would be superior to standard ablation with bonus freeze. METHODS: We enrolled 226 consecutive patients referred for cryoballoon-based PVI. Patients underwent PVI either with the 28-mm Arctic Front Advance (Medtronic, Minneapolis, Mn) cryoballoon using two 4-minute freezes (standard group) or with the POLARx FIT (Boston Scientific, Marlborough, Ma) cryoballoon using 3-minute freezes in both the 28- and 31-mm-diameter configurations (double stack group). Patients were followed for up to 1 year. The primary outcome was atrial tachyarrhythmia recurrence, with peri-procedural complications, cardioversion, emergency department visit, hospitalization, and repeat ablation being secondary outcomes. RESULTS: A total of 226 patients were included (70% male; 47% with persistent atrial fibrillation [AF]). Patients in the double stack group had a significantly greater freedom from recurrent AF/atrial tachycardia/atrial flutter at 1 year (87.2% vs 68.9%; hazard ratio 0.41; 95% confidence interval 0.24-0.71; P=.008). Periprocedural complications were similar between the groups (5.2% vs 3.4%; P=.50). At 1 year, there was no difference in cardioversion (12.8% vs 20.3%; P=.20), emergency department visit (9.0% vs 15.5%; P=.22), or all-cause hospitalization (1.3% vs 2.7%; P=.66). Significantly less patients treated with double stack underwent repeat ablation (1.3% vs 13.5%; P=.002). CONCLUSION: In a mixed cohort of patients with paroxysmal and persistent AF, cryoballoon ablation using the double stack technique is associated with lower rates of AF recurrence, aggregate healthcare utilisation, and lower rates of repeat ablation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of British Columbia, Vancouver, British Columbia, Canada.
- University of British Columbia, Vancouver, British Columbia, Canada; Vancouver General Hospital, Vancouver, British Columbia, Canada; Center for Cardiovascular Innovation, Vancouver, British Columbia, Canada.
- Vancouver General Hospital, Vancouver, British Columbia, Canada.
- Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.
- University of British Columbia, Vancouver, British Columbia, Canada; Vancouver General Hospital, Vancouver, British Columbia, Canada; Center for Cardiovascular Innovation, Vancouver, British Columbia, Canada; Montreal H…
Zitieren
APA
Kibel, S., Bennett, M. T., Bennett, R. G., Deyell, M. W., Simon, F., Bennett, E., Medwid, L., Pearce, C., Macle, L., & Andrade, J. G. (2025). Cryoballoon pulmonary vein isolation: Double stack vs standard ablation. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2025.01.030
Vancouver
Kibel S, Bennett MT, Bennett RG, Deyell MW, Simon F, Bennett E, et al. Cryoballoon pulmonary vein isolation: Double stack vs standard ablation. Heart Rhythm. 2025. doi:10.1016/j.hrthm.2025.01.030
BibTeX
@article{Kibel2025,
author = {Kibel, Seth and Bennett, Matthew T and Bennett, Richard G and Deyell, Marc W and Simon, Fanni and Bennett, Ellaina and Medwid, Leone and Pearce, Corinne and Macle, Laurent and Andrade, Jason G},
title = {Cryoballoon pulmonary vein isolation: Double stack vs standard ablation},
journal = {Heart Rhythm},
year = {2025},
doi = {10.1016/j.hrthm.2025.01.030}
}
EUVIMED